1. Search Result
Search Result
Results for "

bone mineralization

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

7

Peptides

3

Inhibitory Antibodies

9

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0657
    Clodronic acid
    4 Publications Verification

    Clodronate

    Apoptosis Others Cancer
    Clodronic acid is an orally active bisphosphonate, which is used for researching osteoporosis and diseases associated with excessive bone resorption. Clodronic acid inhibits bone resorption through induction of osteoclast apoptosis. Clodronic acid is effective in the maintenance or improvement of bone mineral density .
    Clodronic acid
  • HY-A0020
    Eldecalcitol
    3 Publications Verification

    ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3

    VD/VDR Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
    Eldecalcitol
  • HY-108786

    ENB-0040

    Phosphatase Metabolic Disease
    Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 / knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .
    Asfotase alfa
  • HY-P0007

    Carbocalcitonin

    Drug Intermediate Metabolic Disease
    Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect .
    Elcatonin
  • HY-170788

    Phosphodiesterase (PDE) Metabolic Disease
    PDE7A-IN-1 (Compound 26) is an orally active PDE7A inhibitor with an IC50 value of 3.7 nM. PDE7A-IN-1 significantly improves bone mineral density by inhibiting the sclerostin (sclerostin) and is suitable for the study of osteoporosis and related bone metabolic diseases .
    PDE7A-IN-1
  • HY-P991365

    Transmembrane Glycoprotein Endocrinology
    DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    DS-1501
  • HY-117182

    Apoptosis VD/VDR RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    LG190178 is a non-steroidal vitamin D receptor (VDR) ligand that can induce the formation of heterodimer complexes between VDR and retinoid X receptor (RXR), stabilizing the agonistic conformation of the VDR ligand-binding domain and promoting its interaction with co-activators. LG190178 has functions in regulating calcium homeostasis, bone mineralization, as well as cell proliferation, differentiation, and apoptosis, making it useful for research in psoriasis, osteoporosis, and cancer .
    LG190178
  • HY-A0020R

    ED-71 (Standard); 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3 (Standard)

    Reference Standards VD/VDR Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Eldecalcitol (Standard) is the analytical standard of Eldecalcitol. This product is intended for research and analytical applications. Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
    Eldecalcitol (Standard)
  • HY-P0284

    MMP Inflammation/Immunology
    C-telopeptide, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD).
    C-telopeptide
  • HY-103578

    Androgen Receptor Cancer
    S-40503 is an orally active and selective androgen receptor modulator. S-40503 significantly increases the bone mineral density (BMD) and biomechanical strength of femoral cortical bone .
    S-40503
  • HY-135702

    NF-κB Others
    UBS109, as a curcumin analogue, can promote the differentiation and mineralization of osteoblasts. UBS109 shows to regulate bone cell function by activating Smad and inhibiting NF-kB. UBS109 can be used in bone tissue engineering and osteoporosis research .
    UBS109
  • HY-B1092

    Calcium D-gluconate; Gluconic acid hemicalcium salt

    Endogenous Metabolite Others
    Gluconate Calcium (Calcium D-gluconate) is a mineral supplement, manufactured by the neutralization of gluconic acid with lime or calcium carbonate. Gluconate Calcium can optimize bone and teeth health .
    Gluconate Calcium
  • HY-117817

    Endogenous Metabolite Metabolic Disease
    Ranelic acid is an organic acid with metal cation chelating activity. Ranelic acid can be used to inhibit osteoporosis and increase bone mineral density. Ranelic acid derivatives exhibit highly substituted thiophene ring structures .
    Ranelic acid
  • HY-NP175

    Biochemical Assay Reagents Others
    Collagen (bovine skin) plays an important role in the structure and function of skin, bone, tendons, and many others. Collagen, from bovine skin can be used to provide a scaffold for biomimetic collagen mineralization .
    Collagen (bovine skin)
  • HY-N8837

    MMP Metabolic Disease
    Trifloroside is a secoiridoid glycoside with antioxidant effects. Trifloroside induces osteogenic effects through osteoblast differentiation, adhesion, migration, and mineral apposition. Trifloroside has the potential for osteoblast-mediated bone diseases research .
    Trifloroside
  • HY-153258

    CaSR Metabolic Disease
    CaSR antagonist-1 is a calcium sensing receptor (CaSR) antagonist with an IC50 value of 50 nM. CaSR antagonist-1 can be used for the research of disorders associated with abnormal bone or mineral homeostasis such as osteoporosis .
    CaSR antagonist-1
  • HY-D2132

    Fluorescent Dye Cancer
    Sulfo-Cy5.5-ALN is a fluorescent labeled alendronate, which targets bone. Sulfo-Cy5.5-ALN binds to hydroxyapatite and differentiated osteoblasts in vitro. Sulfo-Cy5.5-ALN selectively binds to the mineralized areas of the tumor. Sulfo-Cy5.5-ALN can be used to detect bone overgrowth in prostate bone metastasis .
    Sulfo-Cy5.5-ALN
  • HY-P4823

    Thyroid Hormone Receptor Metabolic Disease
    pTH (1-37) (human) is a fragment of parathyroid hormone (PTH). pTH (1-37) (human) induces the cAMP formation and increases alkaline phosphatase activity. pTH (1-37) (human) increases growth, bone calcium content, and bone mineral density (BMD) in uremic animals. pTH (1-37) (human) has the potential for the research of osteoporosis .
    pTH (1-37) (human)
  • HY-D0835A

    Hydroxyapatite (<50 nm)

    Biochemical Assay Reagents Cardiovascular Disease Inflammation/Immunology
    Hydroxylapatite (Hydroxyapatite) (<50 nm) is a natural form of calcium phosphate and is the main mineral component of bones and teeth. Hydroxylapatite (<50 nm) can stimulate the expression and secretion of collagen in primary human dermal fibroblasts. Hydroxylapatite (<50 nm) has good biocompatibility, bioactivity, and bone conductivity, making it suitable for targeted drug or nucleic acid delivery. Hydroxylapatite (<50 nm) can be used in research on osteoarthritis, gout, and atherosclerosis .
    Hydroxylapatite (<50 nm)
  • HY-N1499

    Wnt β-catenin TGF-beta/Smad Bacterial Infection Metabolic Disease Inflammation/Immunology
    Nystose is a tetrasaccharide with two fructose molecules linked via beta (1→2) bonds to the fructosyl moiety of sucrose. Nystose exhibits prebiotic, immunomodulatory, and metabolism regulating activities. Nystose promotes the bone mineralization by activating the Wnt/β-catenin signaling pathway .
    Nystose
  • HY-B1092R

    Calcium D-gluconate (Standard); Gluconic acid hemicalcium salt (Standard)

    Reference Standards Endogenous Metabolite Others
    Gluconate (Calcium) (Standard) is the analytical standard of Gluconate (Calcium). This product is intended for research and analytical applications. Gluconate Calcium (Calcium D-gluconate) is a mineral supplement, manufactured by the neutralization of gluconic acid with lime or calcium carbonate. Gluconate Calcium can optimize bone and teeth health .
    Gluconate Calcium (Standard)
  • HY-A0020S

    VD/VDR Metabolic Disease
    Eldecalcitol-d6 is the deuterium labeled Eldecalcitol. Eldecalcitol is an orally active analogue of active vitamin D used in the treatment of osteoporosis.
    Eldecalcitol-d6
  • HY-15099

    VEL 0230

    Cathepsin Inflammation/Immunology
    NC 2300 (VEL-0230)is a selective and orally active cysteine cathepsin inhibitor with the IC50 values of 284, 34.5, and 186 nM for cathepsin B, K, and S, respectively.NC 2300 can be used for study of diseases involving bone mineral disorders .
    NC 2300
  • HY-B2203

    Phosphatase Metabolic Disease
    Monocalcium glycerophosphate is an inhibitor of intestinal alkaline phosphatase F3, and it has anti-cavity properties. Monocalcium glycerophosphate is a source of calcium and phosphorus in total parenteral nutrition solutions, helps prevent the mineralization and development of bones from intravenous nutrition, and maintains the integrity of the intestinal epithelium .
    Monocalcium glycerophosphate
  • HY-D0835

    Hydroxyapatite (25-45 μm)

    Biochemical Assay Reagents Cardiovascular Disease Inflammation/Immunology
    Hydroxylapatite (Hydroxyapatite) (25-45 μm) is a natural form of calcium phosphate and is the main mineral component of bones and teeth. Hydroxylapatite (25-45 μm) can stimulate the expression and secretion of collagen in primary human dermal fibroblasts. Hydroxylapatite (25-45 μm) has good biocompatibility, bioactivity, and bone conductivity, making it suitable for targeted drug or nucleic acid delivery. Hydroxylapatite (25-45 μm) can be used in research on osteoarthritis, gout, and atherosclerosis .
    Hydroxylapatite (25-45 μm)
  • HY-150186

    RXFP Receptor Metabolic Disease
    RXFP2 agonist 2 is a selective, orally active and allosteric RXFP2 agonist with an EC50 value of 0.38 μM. RXFP2 agonist 2 induces osteoblast mineralization. RXFP2 agonist 2 increases bone formation in female mice. RXFP2 agonist 2 has the potential for the research of osteoporosis .
    RXFP2 agonist 2
  • HY-122075

    Others Metabolic Disease
    FR 78844 is a potent and orally active bone resorption inhibitor. FR 78844 has the potential for the research of diabetes associated osteopenia .
    FR 78844
  • HY-N1499R

    Reference Standards Wnt β-catenin TGF-beta/Smad Bacterial Infection Metabolic Disease Inflammation/Immunology
    Nystose (Standard) is the analytical standard of Nystose. This product is intended for research and analytical applications. Nystose is a tetrasaccharide with two fructose molecules linked via beta (1→2) bonds to the fructosyl moiety of sucrose. Nystose exhibits prebiotic, immunomodulatory, and metabolism regulating activities. Nystose promotes the bone mineralization by activating the Wnt/β-catenin signaling pathway .
    Nystose (Standard)
  • HY-D0886
    β-Glycerophosphate disodium salt pentahydrate
    Maximum Cited Publications
    14 Publications Verification

    Phosphatase Endogenous Metabolite ERK Metabolic Disease Cancer
    β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells .
    β-Glycerophosphate disodium salt pentahydrate
  • HY-126304
    β-Glycerophosphate disodium salt hydrate
    Maximum Cited Publications
    14 Publications Verification

    Phosphatase Endogenous Metabolite ERK Metabolic Disease
    β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells .
    β-Glycerophosphate disodium salt hydrate
  • HY-107245
    Segetalin B
    2 Publications Verification

    Estrogen Receptor/ERR Sirtuin RUNX Metabolic Disease
    Segetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP) .
    Segetalin B
  • HY-169703

    RANKL/RANK p38 MAPK Akt NF-κB Inflammation/Immunology
    SPA0355 is a thiourea derivative that has antioxidant and anti-inflammatory properties. SPA0355 inhibits the RANKL (receptor activator of nuclear factor κB ligand) induced osteoclast formation in primary bone marrow-derived macrophages. SPA0355 also suppresses the activation of the MAPKs, Akt, and NF-κB pathways. Additionally, SPA0355 promotes osteoblast differentiation, increases alkaline phosphatase activity, and enhances mineral nodule formation. SPA0355 can protect ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it useful for studying postmenopausal osteoporosis .
    SPA0355
  • HY-W110927

    Biochemical Assay Reagents Fluorescent Dye Others
    Alizarin red S indicator (C.I. 58005) is a reductively active (quinone-based) anthraquinone dye that forms complexes with metal ions (such as zirconium, calcium) or boric acid to label calcium deposition and perform electrochemical sensing functions. Alizarin Red S undergoes reversible redox reactions (for electrochemical detection) and irreversible chelation (for bone staining). Alizarin Red S is mainly used in bone metabolism research (labeling mineralized tissue), sugar detection (boric acid-sugar competition system) and metal ion sensing (such as zirconium ion detection), and can be used in osteoporosis and metabolic disease research .
    Alizarin Red S Indicator (4.3-6.3), IND
  • HY-P0059
    Teriparatide
    5+ Cited Publications

    Human parathyroid hormone-(1-34); hPTH (1-34)

    PTHR Thyroid Hormone Receptor Others Cancer
    Teriparatide (Human parathyroid hormone-(1-34)) is a PTH1 receptor agonist. Teriparatide (Human parathyroid hormone-(1-34)) can be used for osteoporosis research .
    Teriparatide
  • HY-P0059A

    Human parathyroid hormone-(1-34) acetate hydrate; hPTH (1-34) acetate hydrate

    PTHR Thyroid Hormone Receptor Others Cancer
    Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) is a PTH1 receptor agonist. Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) can be used for osteoporosis research .
    Teriparatide acetate hydrate
  • HY-108044
    ONO-5334
    2 Publications Verification

    Cathepsin SARS-CoV Metabolic Disease
    ONO-5334 is a potent, selective and orally active cathepsin K inhibitor with Ki values of 0.10 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively. ONO 5334 is an effective antiviral compound against SAR-COV-2 virus activity with an EC50 value of 500 nM. ONO-5334 has the potential for the study of osteoporosis and COVID-19 disease .
    ONO-5334
  • HY-159595

    LDLR PCSK9 Metabolic Disease Inflammation/Immunology
    PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
    PCSK9-IN-29
  • HY-138089

    Androgen Receptor Estrogen Receptor/ERR LDLR Metabolic Disease Cancer
    17β-Hydroxy exemestane (17-H-EXE) is the primary active metabolite of Exemestane (HY-13632). 17β-Hydroxy exemestane is an aromatase inhibitor (IC50 = 69 nM) and an androgen receptor (AR) agonist (IC50 = 39.6 nM) that is selective for AR over estrogen receptor α (ERα; IC50 = 21.2 μM). 17β-Hydroxy exemestane stimulates growth of AR- and ERα-positive MCF-7 (EC50= 2.7 μM) and T47D breast cancer cells (EC50s = 0.43 and 1500 nM for AR- and ER-mediated growth, respectively) and inhibits proliferation of testosterone-treated aromatase-overexpressing MCF-7 cells. 17β-Hydroxy exemestane inhibits increases in serum cholesterol and LDL levels and prevents decreases in bone mineral density in the lumbar vertebrae and femur, as well as femoral bending strength and compressive strength of the fifth lumbar vertebrae in ovariectomized rats .
    17β-Hydroxy exemestane

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: